Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 25 versus ORETON METHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 25 versus ORETON METHYL.
ANDROID 25 vs ORETON METHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Category C
Category C
Androgen
Androgen